Clinical Trial Update: A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD [Phase 3]

View source ↗

Summary

This update reports results from a 6-month open-label extension of a Phase 3 pediatric major depressive disorder study evaluating DVS SR, focusing on safety, to…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• DVS SR

Snippet

Sponsor: Pfizer | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2017-02-08